611 W. Union Street
Benson, AZ 85602
(520) 586-0800

Health Choice Integrated Care crisis Line
1-877-756-4090

NurseWise 24-Hour Crisis Line
1-866-495-6735

NAZCARE Warm Line
1-888-404-5530



SEABHS
611 W. Union Street
Benson, AZ 85602
(520) 586-0800

NurseWise 24-Hr Crisis Line
1-866-495-6735

NAZCARE Warm Line
1-888-404-5530


powered by centersite dot net

Getting Started
Here are some forms to get started. These can be printed and brought with you so that you can pre-fill out some known info ahead of time. More...


Mental Disorders
Resources
Basic InformationLookupsLatest News
Narrow Networks in ACA Marketplace for Mental HealthHurricanes' Toll on Mental Health Will LingerER Visits for These 3 Health Woes Don't Have to HappenPreventive Psychological, Educational Programs BeneficialPsychosocial Intervention App Feasible in Serious Mental IllnessHealth Tip: Mental Disorders Are CommonNearly 1 in 5 U.S. Adults Has Mental Illness or Drug ProblemHalf of Opioid Prescriptions Go to People With Mental IllnessPsychological Risks Higher in Atopic Dermatitis PatientsSAMHSA: 9.8 Million U.S. Adults Have Serious Mental IllnessNearly 10 Million U.S. Adults Suffer From Mental IllnessSuicide Risk Is High for Psychiatric Patients Long After Discharge From CareStreptococcal Throat Infection Linked to Mental DisordersMental Health Myths Abound in the U.S.Care Access Worsening for Adults With Psychological DistressJust 1 in 5 Mentally Ill Women Gets Cervical Cancer ScreeningsAnxious? Distressed? You're Not AlonePast Psychiatric Disorders Do Not Raise Risk of Alzheimer's DiseasePast Psychiatric Ills Don't Raise Alzheimer's Risk: StudySelf-Harm Can Be a Harbinger of SuicideClimate Change May Cloud Americans' Mental Health: ReportKetamine Beneficial for Certain Patients With Mood DisordersPatients Reluctant to Comply With Drug-Only Psychiatric TreatmentPatients Often Reject Drug-Only Psychiatric TreatmentStudy Links Psychiatric Disorders to Stroke RiskAnxiety, Depression May Up Mortality Risk for Some CancersMental Health May Affect Chances Against CancerObamacare Covered More People With Mental Illness, AddictionsMany With Mental Illness Miss Out on HIV TestsPlastic Surgeons Often Miss Patients' Mental DisordersMortality Risk in T2DM Increased With Depression and/or AnxietyMost Smokers With Mental Illness Want to Kick the HabitRate of Psychiatric Drug Use About 16 Percent in U.S. Adults1 in 6 U.S. Adults Takes a Psychiatric Drug: StudyFor People With Mental Health Woes, Pets Can Be InvaluableHealth Tip: Thinking About Psychological Therapy?Heart Rate, BP in Male Teens Tied to Later Risk for Psych DisordersU.S. Psychiatric Patients Face Long Waits in ERsAre Some Blood Pressure Meds Linked to Depression, Bipolar Risk?Study Links Pot Use to Relapse in Psychosis PatientsU.S. Soldier in Custody Following Slaying of 5 Americans in Iraq
Questions and AnswersLinksBook Reviews
Related Topics

Anxiety Disorders
Bipolar Disorder
Depression: Depression & Related Conditions
Schizophrenia
Eating Disorders

Ketamine Beneficial for Certain Patients With Mood Disorders


HealthDay News
Updated: Mar 8th 2017

new article illustration

WEDNESDAY, March 8, 2017 (HealthDay News) -- Use of ketamine for treatment of mood disorders should include appropriate patient selection and consideration of potential risks of treatment, according to a consensus statement published online March 1 in JAMA Psychiatry.

Gerard Sanacora, M.D., Ph.D., from the Yale University School of Medicine in New Haven, Conn., and colleagues examined data on the use of ketamine for mood disorder treatment.

The researchers note that ketamine may be helpful for some patients with mood disorders. Appropriate patient section should include diagnostic considerations, with the strongest evidence supporting ketamine's benefit in treatment of major depressive disorder without psychotic features, as well as assessment of other medical, psychological, and social factors. Most studies supporting ketamine's benefit assessed efficacy during the first week following a single infusion; emerging studies indicate that repeated dosing may extend the efficacy for at least several weeks. However, the available data are limited and potential risks associated with ketamine should be considered before its use.

"The suggestions provided are intended to facilitate clinical decision making and encourage an evidence-based approach to using ketamine in the treatment of psychiatric disorders considering the limited information that is currently available," the authors write. "This article provides information on potentially important issues related to the off-label treatment approach that should be considered to help ensure patient safety."

Several authors disclosed financial ties to the pharmaceutical industry.

Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)